HanAll Biopharma said it would receive a milestone payment from Roivant Sciences, a Switzerland-based company, for the technology transfer regarding an investigational autoimmune disease treatment HL161 (ingredient: batoclimab).

In a regulatory filing on Wednesday, HanAll said it was scheduled to receive a $17.5 million milestone from Roivant.

The milestone amount represents more than 5 percent of HanAll's consolidated sales of 110 billion won ($84.3 million) last year.

It is a tiered milestone for HL161's global phase 3 trial targeting chronic inflammatory demyelinating polyneuropathy (CIDP).

The company had previously received a $10 million milestone from Roivant in December for HL161's global phase 3 trial for myasthenia gravis.

After licensing-in the HL161 technology from HanAll in 2017, Roivant established Immunovant. Since then, Immunovant has been working on HL161.

HanAll expects additional milestone fees because Immunovant is also preparing a phase 3 study to treat various diseases, including thyroid eye disease, and warm autoimmune hemolytic anemia.

"The technology transfer agreement could be terminated if additional clinical trials, approval, or commercialization are not realized in the future. We do not have an obligation to return our milestone payments even if the deal is terminated," HanAll said in the filing.